Artiva Biotherapeutics (ARTV) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 24, 2025, to be held virtually for stockholders of record as of April 25, 2025.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of Daniel Baker, Ph.D., as Class I director to serve until the 2028 Annual Meeting or until a successor is qualified.

• Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.

• Approval of an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 1,214,580.

Board of directors and corporate governance

• Board recommends a vote in favor of all three proposals presented at the annual meeting.